A Phase 4 interventional study of Cryoanalgesia and Thoracic epidural (ropivicaine, fentanyl) in Pectus Excavatum and Funnel Chest, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2021-05-05.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment
The purpose of this study is to determine whether cryoanalgesia provides better pain control for minimally invasive pectus excavatum repair (the Nuss procedure) than thoracic epidural.
Pain control is a major challenge for physicians, who must ensure appropriate and effective pain control for their patients, while remaining mindful of the many negative effects of opioid dependence and addiction. Nowhere is there a more pressing need than in children and young adults, who are at high risk for drug abuse, and in post-operative care, since post-operative opioid use can be a starting point for long-term pain issues. Postoperative pain control in the Nuss procedure, minimally invasive repair of the congenital chest wall deformity known as pectus excavatum, remains a significant problem for the 3000 patients who undergo this procedure each year, mostly adolescents and young adults. Many multimodal analgesic regimens have been tried, but optimal treatment remains unknown.
This study will test a novel and promising strategy of using intra-operative cryoanalgesia during the Nuss procedure. Cryoanalgesia is the localized, temporary freezing of peripheral nerves, which is performed at the time of the Nuss procedure. The study is a 20-subject prospective, randomized pilot trial comparing cryoanalgesia to thoracic epidural analgesia for post-operative pain control in patients undergoing the Nuss procedure. Subjects will be recruited from patients already scheduled for a Nuss procedure at our institution, and will undergo 1:1 randomization to either cryoanalgesia or thoracic epidural analgesia for perioperative pain control. During their hospitalization, patients' opiate usage will be prospectively recorded, and pain will be assessed twice per day. Upon discharge, patients will maintain a log of their opiate use, and will return to clinic at 2 weeks, 1 month, 3 months, and 1 year after Nuss procedure for post-operative assessment. Primary outcome is length of perioperative hospitalization, an objective measure that synthesizes many different aspects of a procedure and its subsequent post-operative course, including pain control. Secondary outcomes are post-operative narcotic usage and direct cost of perioperative hospitalization. Side effects of both interventions will also be assessed.
This will be the first systematic investigation of cryoanalgesia for local nerve block in a thoracoscopic procedure, and the first study involving its use in adolescents and young adults. The results will have direct application for those undergoing the Nuss procedure to repair pectus excavatum. Investigators will also delineate a reproducible protocol for delivering cryoanalgesia thoracoscopically, to ensure others can safely and effectively use this method if it proves beneficial. Although the focus is on the small subset of patients who undergo the Nuss procedure, if a standardized approach to cryoanalgesia delivery in a thoracoscopic procedure has a positive effect on patient outcomes and cost of hospitalization, the technique could be applied to a variety of surgical procedures, as well as for other neuropathic pain.
79 studies on the registry are indexed under Funnel Chest; 10 are open to participants now.
This study's enrollment of 20 is below the median of 40 across 46 interventional studies indexed under Funnel Chest.
Browse Funnel Chest studies →University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
Device: Cryoanalgesia
Thoracic epidural (ropivicaine, fentanyl).
Drug: Thoracic epidural (ropivicaine, fentanyl)
Also known as: AtriCure, cryoprobe, nerve freezing
Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
Also known as: Epidural
Length of Hospitalization
the length of the patient's in-hospital stay following admission for Nuss procedure
Time frame: estimated one week or less
Narcotic Usage
Inpatient narcotic usage
Time frame: Post Operative Hospital Stay
Mean Neuropathic Pain Score at One Year
Neuropathic specific pain (described as "burning", "electrical" or "tingling" sensations) was assessed by study questionnaire via numerical pain scale (1 to 10, with 10 representing a maximum score, or worst pain possible).
Time frame: one year
Cost Analysis
cost analysis of initial hospitalization following Nuss procedure
Time frame: estimated one week
Twenty consecutive patients were recruited from those scheduled for the Nuss procedure.
| Milestone | Cryoanalgesia | Thoracic Epidural |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
| Milestone | Cryoanalgesia | Thoracic Epidural |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
the length of the patient's in-hospital stay following admission for Nuss procedure
| Length of Stay (Post-Operative Days) | Cryoanalgesia | Thoracic Epidural |
|---|---|---|
| Length of Hospitalization | 3 (2 to 4) | 5 (4 to 6) |
Inpatient narcotic usage
| mg | Cryoanalgesia | Thoracic Epidural |
|---|---|---|
| Narcotic Usage | 268 ± 165.2 | 684 ± 191.8 |
Neuropathic specific pain (described as "burning", "electrical" or "tingling" sensations) was assessed by study questionnaire via numerical pain scale (1 to 10, with 10 representing a maximum score, or worst pain possible).
| score on a scale | Cryoanalgesia | Thoracic Epidural |
|---|---|---|
| Mean Neuropathic Pain Score at One Year | 2.4 ± 2.69 | 1.9 ± 1.34 |
cost analysis of initial hospitalization following Nuss procedure
No measurements were reported for this outcome.
Collected over All adverse events reported post operatively at the 2 week, 1 month, 3 month and 1 year follow up points were collected. In addition all serious adverse events that occurred following enrollment were as well collected. The collection period for all serious adverse events began after informed consent was obtained and ended after procedures for the final study visit had been completed at the 1 year post-operative mark.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cryoanalgesia | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Thoracic Epidural | 0/10 (0%) | 2/10 (20%) | 0/10 (0%) |
| Event | Cryoanalgesia | Thoracic Epidural |
|---|---|---|
| Symptomatic PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/10 | 1/10 |
| Urinary RetentionRenal and urinary disorders | 0/10 | 1/10 |
| ParaplegiaNervous system disorders | 0/10 | 0/10 |
| Wound InfectionInfections and infestations | 0/10 | 0/10 |
| Infection from indwelling thoracic epidural catheterInfections and infestations | 0/10 | 0/10 |
| Age, Categorical(Participants) | Cryoanalgesia | Thoracic Epidural | Total |
|---|---|---|---|
| <=18 years | 4 | 7 | 11 |
| Between 18 and 65 years | 6 | 3 | 9 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Cryoanalgesia | Thoracic Epidural | Total |
|---|---|---|---|
| Mean | 20.9 (14 to 31) | 16.1 (13 to 21) | 18.5 (13 to 31) |
| Sex: Female, Male(Participants) | Cryoanalgesia | Thoracic Epidural | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 9 | 8 | 17 |
| Race and Ethnicity Not Collected(Participants) | Cryoanalgesia | Thoracic Epidural | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Cryoanalgesia | Thoracic Epidural | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2016 to primary completion in Aug 2018, 27 months.
Results were first posted in May 2021, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →